ProKidney
PROK · Nasdaq · United States
Share price · PROK
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PROK's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 2 Nov 2026-13.5%
Nothing announced by PROK that day or the session before.
- 30 Oct 2026-11.9%
- 27 Oct 2026+11.4%
Nothing announced by PROK that day or the session before.
- 5 Oct 2026-8.1%
- 21 Sep 2026-7.1%
Nothing announced by PROK that day or the session before.
- 21 Aug 2026+13.4%
Nothing announced by PROK that day or the session before.
- 12 Aug 2026-8.1%
- Day beforeEarnings date (period ending 2026-06-30)
- 30 Jun 2026+7.9%
Nothing announced by PROK that day or the session before.
- 3 Jun 2026-8.9%
- 17 Apr 2026+11.8%
Nothing announced by PROK that day or the session before.
Share of unusual movement by asset
For each asset, the share of PROK's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Rilparencel(Neo-Kidney Augment / REACT) | Phase 3 | Selected renal cells (autologous, paracrine)Cell therapy | Chronic Kidney Disease |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2029 (1)
December 2029 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0.2M | $41M | $81M | $36M-$39M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0.1M | $36M | $75M | $28M-$40M operating cash flow | report ↗ |
| 2026-Q1 | $0.2M | $34M | $102M | $20M-$42M operating cash flow | report ↗ |
| 2025-Q3 | $0.2M | $27M | $95M | $16M-$27M operating cash flow | report ↗ |
| 2025-Q2 | $0.2M | $26M | $85M | $17M-$31M operating cash flow | report ↗ |
| 2025-Q1 | $0.2M | $27M | $98M | $17M-$30M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $31M | $108M | $18M-$29M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $29M | $215M | $13M-$38M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $27M | $84M | $9.5M-$35M operating cash flow | report ↗ |
| 2023-Q3 | — | $32M | $191M | $11M-$24M operating cash flow | report ↗ |
| 2023-Q2 | — | $26M | $244M | $9.1M-$15M operating cash flow | report ↗ |
| 2023-Q1 | — | $26M | $272M | $9.7M-$26M operating cash flow | report ↗ |
| 2022-Q3 | — | $21M | $506M | $30M-$61M operating cash flow | report ↗ |
| 2022-Q2 | — | $12M | $0.1M | $2.3M-$0.2M operating cash flow | report ↗ |
| 2022-Q1 | — | $28M | $0.1M | $4.0M-$0.4M operating cash flow | report ↗ |
| 2021-Q3 | — | $15M | $4.1M | $0.3M-$1.1M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.9M | $114M | $109M | $17M-$120M operating cash flow | report ↗ |
For full year 2025, ProKidney reported revenue of $0.89M, up 1012.5% YoY, with R&D spend of $114.12M, down 10.6% YoY. Cash and equivalents were $108.54M, while total cash, cash equivalents and marketable securities were $270.0M. Net loss available to Class A common stockholders was $68.99M, reflecting a quarterly net burn of $68.99M.
The company expects existing cash to fund operations into mid-2027. It remains on track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026, with pivotal topline results expected in Q2 2027, and aligned with the FDA in July 2025 on the accelerated approval pathway using eGFR slope. Positive Phase 2 REGEN-007 results were presented at ASN Kidney Week 2025 and published in CJASN, and expansion of the in-house manufacturing footprint was initiated in Winston-Salem.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 6 sales ($1.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-02 | Culleton Bruce · director, Chief Executive Officer | Award / grant (derivative) | 500,000 | — | — | Form 4 |
| 2026-10-28 | Weber Darin J. · Chief Regulatory Officer | Conversion | 200,000 | — | — | Form 4 |
| 2026-10-28 | Weber Darin J. · Chief Regulatory Officer | Conversion (derivative) | 200,000 | — | — | Form 4 |
| 2026-10-28 | Weber Darin J. · Chief Regulatory Officer | Conversion (derivative) | 200,000 | — | — | Form 4 |
| 2026-08-20 | Pereira Brian JG · director | Open-market sale | 222,948 | $1.42 | $317K | Form 4 |
| 2026-08-20 | Pereira Brian JG · director | Open-market sale | 27,052 | $1.42 | $38K | Form 4 |
| 2026-08-19 | Pereira Brian JG · director | Open-market sale | 222,949 | $1.44 | $321K | Form 4 |
| 2026-08-19 | Pereira Brian JG · director | Open-market sale | 27,051 | $1.44 | $39K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 69 reporting institutions held 42.7M shares ($75.8M, 14.1% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | SUVRETTA CAPITAL MANAGEMENT, LLC | 12,341,266 | $22.1M |
| 2 | MORGAN STANLEY | 8,955,967 | $16.0M |
| 3 | MILLENNIUM MANAGEMENT LLC | 2,271,577 | $4.1M |
| 4 | Bleichroeder LP | 2,000,000 | $3.6M |
| 5 | Artia Global Partners LP | 1,806,939 | $3.2M |
| 6 | Hennion & Walsh Asset Management, Inc. | 1,611,693 | $2.9M |
| 7 | BlackRock, Inc. | 1,387,116 | $2.5M |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 1,250,794 | $2.2M |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1,230,409 | $2.2M |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 1,146,937 | $2.1M |
| 11 | MARSHALL WACE, LLP | 1,011,744 | $1.8M |
| 12 | BANK OF AMERICA CORP /DE/ | 753,412 | $1.3M |
| 13 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 627,771 | $1.1M |
| 14 | STATE STREET CORP | 556,845 | $997K |
| 15 | VANGUARD FIDUCIARY TRUST CO | 538,371 | $964K |